Viatris Inc Ord Shs Stock Price, News & Analysis

Viatris reported strong first-quarter 2022 results, achieving total revenues of $4.19 billion and U.S. GAAP net earnings of $399.2 million. Adjusted EBITDA stood at $1.59 billion, with free cash flow reaching $1.07 billion. The company confirmed its $600 million new product revenue target and made significant progress on its debt repayment strategy, paying down $840 million of debt. Additionally, a quarterly dividend of $0.12 per share was declared. The ongoing conflict in Ukraine has had limited immediate impact but poses potential future risks.

Viatris Inc. (NASDAQ: VTRS) will announce its Q1 2022 financial results on May 9, 2022, before U.S. market opening. The announcement will be followed by a live webcast at 8:30 a.m. EDT, featuring executives including CEO Michael Goettler and CFO Sanjeev Narula. The company aims to provide insights on its performance since being formed in November 2020, leveraging extensive expertise to deliver high-quality medicines globally.

On March 30, 2022, Viatris Inc. (NASDAQ: VTRS) partnered with Sesame Workshop to launch new bilingual resources to support the emotional and social needs of families impacted by the COVID-19 pandemic. This initiative includes five videos featuring popular characters like Elmo and Grover, aimed at helping children and caregivers navigate emotions and adapt to changes. The project is part of the Caring for Each Other initiative, reaching families in over 100 countries. Viatris's commitment to global health is highlighted as they continue to provide resources to ease anxieties stemming from the pandemic.

Viatris Inc. (NASDAQ: VTRS) announced a significant legal victory as the U.S. Court of Appeals for the Federal Circuit upheld the invalidity of Biogen's U.S. Patent No. 8,399,514, which covers its multiple sclerosis drug, Tecfidera^®. The court denied Biogen's request to reconsider its earlier ruling, reinforcing that the patent remains invalid. This decision is crucial for Viatris, particularly after its subsidiary, Mylan Pharmaceuticals, launched the first generic equivalent of Tecfidera in August 2020, potentially enhancing market competition and access for patients.

Viatris Inc. (NASDAQ: VTRS) has received FDA approval for Breyna™, the first generic version of AstraZeneca's Symbicort® inhalation aerosol, in partnership with Kindeva Drug Delivery. Available in two dosage strengths, Breyna is indicated for asthma and COPD patients, providing a new treatment option to millions. This approval showcases Viatris' expertise in developing complex generic medicines and supports their mission to enhance patient access. The launch is expected in 2022, subject to ongoing court proceedings that may influence market entry.

Viatris Inc. (NASDAQ: VTRS) announced its participation in two upcoming investor conferences. CEO Michael Goettler and CFO Sanjeev Narula will take part in a fireside chat at the Raymond James 43rd Annual Institutional Investors Conference on March 8 at 3:25 p.m. EST. Additionally, Rajiv Malik, President, and CFO Narula will participate in the Barclays Global Healthcare Conference on March 16 at 10:45 a.m. EST. Live webcasts will be available at investor.viatris.com.

Viatris announced a significant transaction involving Biocon Biologics, with a pre-tax consideration of up to $3.335 billion. This includes $2 billion in upfront cash, $1 billion in convertible preferred equity, and up to $335 million in additional payments. Viatris' President, Rajiv Malik, will join Biocon Biologics' Board. The transaction is expected to close in the second half of 2022, enhancing capital availability for reinvestment and simplifying operational complexity. Viatris also provided 2022 financial guidance, projecting an adjusted EBITDA of approximately $200 million for its biosimilars portfolio.

Viatris Inc. (NASDAQ: VTRS) will host an investor event on February 28, 2022, at 8:30 a.m. ET, where the CEO, President, and CFO will present the company's fourth quarter and full year 2021 financial results. The event will provide insights into Viatris' two-phased strategic roadmap. Interested investors can access a live webcast at investor.viatris.com, with an archived version available afterward. Viatris focuses on delivering high-quality medicines globally, with over 1,400 approved molecules across various therapeutic areas.

Viatris Inc. (NASDAQ: VTRS) announced FDA approval for Cyclosporine Ophthalmic Emulsion 0.05%, the first generic version of Allergan's Restasis®, allowing immediate market launch. With no remaining regulatory barriers, Viatris aims to enhance access to affordable treatments for chronic dry eye disease. This approval represents a significant milestone for Viatris, highlighting its commitment to innovation and patient access.